Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: A meta-analysis of randomized, controlled trials

Clinical Cardiology

Volumn 34, Issue 6, 2011, Pages 395-400

  Hu, Bo ^a   Li, Wei ^a   Xu, Tao ^a   Chen, Tao ^a   Guo, Jin ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TRIMETAZIDINE;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CONFIDENCE INTERVAL; DIABETES MELLITUS; DRUG EFFICACY; ECHOCARDIOGRAPHY; EMBASE; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE WALL MOTION; HEMODYNAMICS; HUMAN; LITERATURE; MAJOR CLINICAL STUDY; MALE; MEDLINE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCINTIANGIOGRAPHY; STABLE ANGINA PECTORIS;

AGED; ANGINA PECTORIS; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RADIONUCLIDE ANGIOGRAPHY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; TRIMETAZIDINE; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 79958281461     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20888     Document Type: Article

References (30)

1. Lopez AD., Assessing the burden of mortality from cardiovascular diseases. World Health Stat Q. 1993; 46: 91-96. (Pubitemid 24017907)
2. Murray CJ, Lopez AD., Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997; 349: 1269-1276. (Pubitemid 27192468)
3. Gillum RF., Trends in acute myocardial infarction and coronary heart disease death in the United States. J Am Coll Cardiol. 1994; 23: 1273-1277. (Pubitemid 24157993)
4. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999; 281: 1927-1936. (Pubitemid 29242807)
5. Hilton TC, Chaitman BR., The prognosis in stable and unstable angina. Cardiol Clin. 1991; 9: 27-38.
6. Birnbaum Y, Criger DA, Wagner GS, et al. Prediction of the extent and severity of left ventricular dysfunction in anterior acute myocardial infarction by the admission electrocardiogram. Am Heart J. 2001; 141: 915-924. (Pubitemid 32477002)
7. Greenblatt DJ, Sellers EM, Shader RI., Drug therapy: drug disposition in old age. N Engl J Med. 1982; 306: 1081-1088. (Pubitemid 12111437)
8. Peduzzi P, Kamina A, Detre K., Twenty-two-year follow-up in the VA Cooperative Study of Coronary Artery Bypass Surgery for Stable Angina. Am J Cardiol. 1998; 81: 1393-1399. (Pubitemid 28283817)
9. Stanley WC, Recchia FA, Lopaschuk GD., Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005; 85: 1093-1129. (Pubitemid 40894649)
10. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000; 86: 580-588. (Pubitemid 30165050)
11. Cross HR., Trimetazidine for stable angina pectoris. Expert Opin Pharmacother. 2001; 2: 857-875. (Pubitemid 32750342)
12. Marzilli M, Klein WW., Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis. 2003; 14: 171-179. (Pubitemid 36543420)
13. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17: 1-12. (Pubitemid 26120810)
14. Fragasso G, Piatti Md PM, Monti L, et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003; 146: E18.
15. El-Kady T, El-Sabban K, Gabaly M, et al. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs. 2005; 5: 271-278. (Pubitemid 40994269)
16. Rosano GM, Vitale C, Sposato B, et al. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol. 2003; 2: 16.
17. Thrainsdottir IS, von Bibra H, Malmberg K, et al. Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. J Cardiovasc Pharmacol. 2004; 44: 101-108. (Pubitemid 38857135)
18. Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J. 2004; 25: 1814-1821. (Pubitemid 39330232)
19. Fragasso G, Perseghin G, De Cobelli F, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006; 27: 942-948.
20. Di Napoli P, Di Giovanni P, Gaeta MA, et al. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy. Am Heart J. 2007; 154: 602e1-e5.
21. Belardinelli R, Purcaro A., Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J. 2001; 22: 2164-2170. (Pubitemid 33139462)
22. Belardinelli R, Lacalaprice F, Faccenda E, et al. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation. Eur J Cardiovasc Prev Rehabil. 2008; 15: 533-540.
23. Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006; 48: 992-998. (Pubitemid 44292461)
24. Brottier L, Barat JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J. 1990; 11: 207-212. (Pubitemid 20119783)
25. McClellan KJ, Plosker GL., Trimetazidine: a review of its use in stable angina pectoris and other coronary conditions. Drugs. 1999; 58: 143-157. (Pubitemid 29373894)
26. Lopaschuk GD., Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis. 2001; 12 (suppl 1): S8-S11.
27. Di Napoli P, Taccardi AA, Barsotti A., Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart. 2005; 91: 161-165.
28. Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double blind, multicentre study (TRIMPOL II). Eur Heart J. 2001; 22: 2267-2274. (Pubitemid 34000982)
29. Aksöyek S, Kabukçu M, Ovünç K, et al. Clinical efficacy of trimetazidine in stable angina pectoris: a double blind placebo controlled study [in Turkish]. Turk Kardiyol Dern Ars. 1996; 24: 289-292.
30. Sellier P, Harpey C, Corona P, et al. Acute effects of trimetazidine on ergometric parameters in effort angina. Cardiovasc Drugs Ther. 1990; 4 (Suppl 4): 820-821. (Pubitemid 20294646)